Therapeutic potential of the latest oxygen affinity-modifying agent, GBT021601, for treating sickle cell disease is questionable.
作者信息
Alaimo Braydon, Metaferia Belhu, Cellmer Troy, Thein Swee Lay, Bunn H Franklin, Eaton William A
机构信息
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Br J Haematol. 2024 Dec;205(6):2527-2529. doi: 10.1111/bjh.19697. Epub 2024 Nov 6.
Abstract
摘要
Zotero 插件